| Guidelines for the use of flow cytometry and cell sorting in immunological studies A Cossarizza, HD Chang, A Radbruch, A Acs, D Adam, S Adam‐Klages, ... European journal of immunology 49 (10), 1457-1973, 2019 | 1715 | 2019 |
| The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis G Van Assche, A Dignass, J Panes, L Beaugerie, J Karagiannis, M Allez, ... Journal of Crohn's and Colitis 4 (1), 7-27, 2010 | 1343 | 2010 |
| Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management A Dignass, JO Lindsay, A Sturm, A Windsor, JF Colombel, M Allez, ... Journal of Crohn's and Colitis 6 (10), 991-1030, 2012 | 1286 | 2012 |
| The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease M Harbord, V Annese, SR Vavricka, M Allez, M Barreiro-de Acosta, ... Journal of Crohn's and Colitis 10 (3), 239-254, 2016 | 805 | 2016 |
| CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease N Barnich, FA Carvalho, AL Glasser, C Darcha, P Jantscheff, M Allez, ... The Journal of clinical investigation 117 (6), 1566-1574, 2007 | 690 | 2007 |
| Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial D Laharie, A Bourreille, J Branche, M Allez, Y Bouhnik, J Filippi, F Zerbib, ... The Lancet 380 (9857), 1909-1915, 2012 | 643 | 2012 |
| Systemic human ILC precursors provide a substrate for tissue ILC differentiation AI Lim, Y Li, S Lopez-Lastra, R Stadhouders, F Paul, A Casrouge, ... Cell 168 (6), 1086-1100. e10, 2017 | 465 | 2017 |
| Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn’s disease J Panés, D García-Olmo, G Van Assche, JF Colombel, W Reinisch, ... Gastroenterology 154 (5), 1334-1342. e4, 2018 | 459 | 2018 |
| Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II G Malamut, P Afchain, V Verkarre, T Lecomte, A Amiot, D Damotte, ... Gastroenterology 136 (1), 81-90, 2009 | 433 | 2009 |
| Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease P Desreumaux, A Foussat, M Allez, L Beaugerie, X Hébuterne, Y Bouhnik, ... Gastroenterology 143 (5), 1207-1217. e2, 2012 | 420 | 2012 |
| Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease L Beaugerie, M Svrcek, P Seksik, AM Bouvier, T Simon, M Allez, H Brixi, ... Gastroenterology 145 (1), 166-175. e8, 2013 | 408 | 2013 |
| Incidence of autoimmune diseases in celiac disease: protective effect of the gluten-free diet J Cosnes, C Cellier, S Viola, JF Colombel, L Michaud, J Sarles, JP Hugot, ... Clinical Gastroenterology and Hepatology 6 (7), 753-758, 2008 | 400 | 2008 |
| Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects M Allez, K Karmiris, E Louis, G Van Assche, S Ben-Horin, A Klein, ... Journal of Crohn's and Colitis 4 (4), 355-366, 2010 | 371 | 2010 |
| Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy M Allez, M Lemann, J Bonnet, P Cattan, R Jian, R Modigliani Official journal of the American College of Gastroenterology| ACG 97 (4 …, 2002 | 355 | 2002 |
| Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation JA Snowden, R Saccardi, M Allez, S Ardizzone, R Arnold, R Cervera, ... Bone marrow transplantation 47 (6), 770-790, 2012 | 342 | 2012 |
| Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel disease L Peyrin-Biroulet, M Ferrante, F Magro, S Campbell, D Franchimont, ... Journal of Crohn's and Colitis 5 (5), 477-483, 2011 | 329 | 2011 |
| Infliximab reduces endoscopic, but not clinical, recurrence of Crohn’s disease after ileocolonic resection M Regueiro, BG Feagan, B Zou, J Johanns, MA Blank, M Chevrier, ... Gastroenterology 150 (7), 1568-1578, 2016 | 318 | 2016 |
| IL-12 drives functional plasticity of human group 2 innate lymphoid cells AI Lim, S Menegatti, J Bustamante, L Le Bourhis, M Allez, L Rogge, ... Journal of Experimental Medicine 213 (4), 569-583, 2016 | 314 | 2016 |
| Early administration of azathioprine vs conventional management of Crohn's disease: a randomized controlled trial J Cosnes, A Bourrier, D Laharie, S Nahon, Y Bouhnik, F Carbonnel, ... Gastroenterology 145 (4), 758-765. e2, 2013 | 305 | 2013 |
| Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients … G D’Haens, S Vermeire, G Lambrecht, F Baert, P Bossuyt, B Pariente, ... Gastroenterology 154 (5), 1343-1351. e1, 2018 | 302 | 2018 |
Philippe SeksikPU-PH UPMCVerified email at sat.aphp.fr
